Eli Lilly and Company (LLY) 86.76 $LLY
3 Big-Cap Drugmakers Who Beat Q2 Earnings Estimates
at Investor's Business Daily - 1 hr 22 mins ago
Large-cap drugmakers Valeant Pharmaceuticals, Eli Lilly and Bristol-Myers Squibb all beat analysts' Q2 estimates, but their stocks went in different directions, as their guidance was more mixed. Valeant (VRX) rose more than 6% after it said total...
VRX: 253.84 (+14.92), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13)
Lilly (Eli) (LLY) Earnings Report: Q2 2015 Conference Call Transcript
at The Street - 1 hr 55 mins ago
The following Lilly (Eli) (LLY) conference call took place on July 23, 2015, 09:00 AM ET. This is a transcript of that earnings call:
LLY: 86.76 (+0.38)
Dow Sheds Yearly Gains as AmEx, Caterpillar Slide
at The Street - Thu Jul 23, 3:07PM CDT
The Dow Jones Industrial Average says goodbye to hard-earned yearly gains on Thursday as major components American Express and Caterpillar sell off.
XLB: 46.09 (-0.68), AXP: 77.01 (-1.98), LLY: 86.76 (+0.38), UA: 95.93 (+6.56), BHP: 36.92 (-0.78), VALE: 5.28 (-0.11), QCOM: 61.78 (-2.41), GM: 31.50 (+1.20), MCD: 97.09 (-0.49), CAT: 76.88 (-2.88), RIO: 38.53 (-0.50), CMCSA: 62.47 (-2.03), SNDK: 63.70 (+9.52)
Eli Lilly, Biogen Present Data at Alzheimer's Association - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 2:55PM CDT
Eli Lilly (LLY) and Biogen presented data on their Alzheimer's disease candidates, solanezumab and aducanumab, respectively at the Alzheimer's Association.
BIIB: 385.05 (-6.69), AGIO: 118.42 (+1.04), AMAG: 71.31 (-1.23), LLY: 86.76 (+0.38)
Dow Turns Negative for 2015 as Losses Accelerate
at The Street - Thu Jul 23, 2:10PM CDT
Stocks are lower on Thursday afternoon as crude oil extends recent lows.
XLB: 46.09 (-0.68), AXP: 77.01 (-1.98), BAC: 18.18 (-0.27), LLY: 86.76 (+0.38), UA: 95.93 (+6.56), IBM: 161.73 (+1.38), VALE: 5.28 (-0.11), BHP: 36.92 (-0.78), QCOM: 61.78 (-2.41), XLK: 42.59 (-0.09), GM: 31.50 (+1.20), MCD: 97.09 (-0.49), CAT: 76.88 (-2.88), RIO: 38.53 (-0.50), MSFT: 46.11 (+0.57), AAPL: 125.16 (-0.06), CMCSA: 62.47 (-2.03), DOW: 47.76 (-2.24), BABA: 83.88 (-0.27)
Don't Sell Qualcomm; Stick With Companies That Have Growth
at The Street - Thu Jul 23, 2:04PM CDT
The CNBC 'Fast Money' traders debate whether now is a good time to sell Qualcomm, and discuss a raft of other stocks.
AMZN: 482.18 (-6.09), NKE: 114.00 (-0.09), FB: 95.44 (-1.60), PFE: 34.78 (-0.10), C: 59.87 (-0.47), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13), INTC: 28.59 (-0.01), HPQ: 31.23 (+0.46), FINL: 27.44 (-0.43), NFLX: 110.10 (-1.40), UA: 95.93 (+6.56), JPM: 69.64 (-0.44), IBM: 161.73 (+1.38), QCOM: 61.78 (-2.41), FFIV: 127.68 (+9.18), CRUS: 35.72 (+5.01), GOOGL: 674.73 (-20.37), FL: 69.90 (-0.36), AAPL: 125.16 (-0.06), FTNT: 46.83 (+4.53), CSCO: 28.01 (+0.48)
Shire Lifts 2015 Guidance On Strong Drug Pipeline
at Investor's Business Daily - Thu Jul 23, 1:42PM CDT
Shire (SHPG) missed analysts' targets for second-quarter earnings and sales but lifted its outlook, citing a strong drug pipeline. The Irish drugmaker's adjusted Q2 earnings per share fell a penny to 88 cents, missing by 5 cents. Operating income on...
VRX: 253.84 (+14.92), SHPG: 261.24 (+1.78), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13)
AmerisourceBergen Beats on 3Q15 Earnings, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 12:36PM CDT
AmerisourceBergen Corp. (ABC) posted earnings of $1.20 per share in the third quarter of fiscal 2015 beating the Zacks Consensus Estimate of $1.15.
ABC: 110.12 (-4.83), WBA: 95.48 (-1.16), LLY: 86.76 (+0.38)
Eli Lilly Beats on 2Q Earnings by Wide Margin, Ups View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Jul 23, 12:10PM CDT
Eli Lilly's (LLY) second quarter results were better-than-expected despite the negative impact of currency movement and genericization.
SNSS: 3.47 (-0.05), LGND: 104.65 (-1.65), AMAG: 71.31 (-1.23), LLY: 86.76 (+0.38)
Lilly Diabetes and NASCAR XFINITY Series Driver Ryan Reed Want You to Think About Your Diabetes Pit Crew
PR Newswire - Thu Jul 23, 11:04AM CDT
To emphasize the importance of a support system in diabetes management, Lilly Diabetes and NASCAR XFINITY Series driver Ryan Reed will kick off the My Diabetes Pit Crew Sweepstakes today in association with the Lilly Diabetes 250, the NASCAR XFINITY Series race in Indianapolis. The sweepstakes hopes to encourage people with diabetes to acknowledge the people who have supported them throughout their diabetes journey.
LLY: 86.76 (+0.38)
Nasdaq Higher as Tech Stocks Rebound
at The Street - Thu Jul 23, 10:00AM CDT
The Nasdaq is the best performer as technology stocks rebound from Wednesday's selloff.
AXP: 77.01 (-1.98), BAC: 18.18 (-0.27), LLY: 86.76 (+0.38), CI: 154.36 (+3.29), UA: 95.93 (+6.56), ANTM: 155.21 (+0.11), IBM: 161.73 (+1.38), QCOM: 61.78 (-2.41), XLK: 42.59 (-0.09), MCD: 97.09 (-0.49), GM: 31.50 (+1.20), CAT: 76.88 (-2.88), MSFT: 46.11 (+0.57), AAPL: 125.16 (-0.06), CMCSA: 62.47 (-2.03), DOW: 47.76 (-2.24), BABA: 83.88 (-0.27)
Lilly, Bristol-Myers Beat Q2 Views, Lift Guidance
at Investor's Business Daily - Thu Jul 23, 9:58AM CDT
Big pharmas Eli Lilly (LLY) and Bristol-Myers Squibb (BMY) both soundly beat Q2 earnings estimates Thursday morning. Both also raised guidance, but not as much as their quarterly beats seemed to warrant. Lilly's profit, excluding one-time items, rose...
LLY: 86.76 (+0.38), BMY: 68.24 (-1.13)
Pharmaceutical Anti-Counterfeiting Technologies Market, 2015-2025 - Authentication Technologies & Track & Trace Technologies
M2 - Thu Jul 23, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3pbvf6/pharmaceutical) has announced the addition of the "Pharmaceutical Anti-Counterfeiting Technologies Market, 2015-2025" report to their offering. The Pharmaceutical Anti-Counterfeiting Technologies, 2015-2025' report provides a comprehensive study of the growing market of anti-counterfeiting technologies being used in the pharmaceutical industry. This study provides extensive details on technologies which offer overt and covert features to enable verification of drugs. In addition, it reviews the different track and trace technologies which enable tracking of a product through the supply chain. Counterfeiting of products is a big concern in several industries such as electronics, cosmetics, tobacco, wine & spirits and fast moving consumer goods. Specifically, within the pharmaceutical market, the magnitude of the problem is relatively high as it has a direct impact on the health of the wider community. It is worth highlighting that the pharmaceutical market is highly attractive for counterfeiters due to several benefits such as high price of patented drugs, lack of proper legislations and high demand of medicines compared to their supply. The primary goal of anti-counterfeiting technologies is to prevent counterfeiting of products; this is done by making it difficult to copy patent protected drugs as well as preventing entry of substandard or fake drugs into the product supply chain. The market can be categorised into two segments, Authentication Technologies (the technologies providing overt and covert security features) and Track & Trace Technologies (the technologies facilitating visibility of products throughout the supply chain). Specifically in the Authentication segment, technologies providing covert security features are very popular and occupy a major share in of the overall authentication market. These technologies are very difficult to mimic and require special instruments / devices for verification of drugs by the manufacturers. Managing supply chain, especially in case of pharmaceutical industry, is a big challenge. Pharmaceuticals supply chains are highly complex and therefore make it an ideal target for counterfeiters. However, recently many developments have taken place to overcome this challenge. Several countries across the globe have passed legislations, making it mandatory to implement serialisation by the manufacturers. Serialisation is being thought as a one stop solution to prevent counterfeiting in the pharmaceutical industry by securing the supply chain. The field has attracted several companies which have developed many technologies with an aim to prevent counterfeiting in the pharma industry. The overall interest continues to rise as is evident from the number of counterfeit incidents and various laws and legislations being passed throughout the world. Small companies that have developed anti-counterfeiting technologies are likely to play a very active role in the near future. Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. Market Overview 5. Authentication: Key Players and Technologies 6. Track And Trace: Key Technologies and the Concept of Serialisation 7. Market Forecast 8. SWOT Analysis 9. Interview Transcripts 10. Conclusion 11. Appendix 1: Tabulated Data 12. Appendix 2: Companies and Organisations Listed Companies Mentioned - 35 of the 125 Companies Featured - 3M - 3S Simons Security Systems - ACG-Worldwide - Acsis - Alcan Packaging - Alien Technology - Alliance for Safe Online Pharmacies - AlpVision - Amcor - Amgen - Applied DNA Sciences - Atlantic Zeiser - Authentix - Avery Dennison - Axway - Ball Packaging - Bilcaretech - Biocode - Bosch Packaging Technology - Canadadrugs.com - Catalent Pharma - Cellular Bioengineering - Central Anti-Counterfeiting Laboratory - Chesapeake (Acquired by The Carlyle Group) - Cognizant - Confidex - Coresonant - Covectra - Deutsche Welle - DiNova Venture Capital - DNA Technologies - Dupont - Eli Lilly and Company - EM Microelectronics - European Alliance of Access to Safe Medicines For more information visit http://www.researchandmarkets.com/research/3p...maceutical
APDN: 2.66 (unch), AMGN: 164.10 (-0.15), LLY: 86.76 (+0.38)
Valeant Earnings Soar On M&A, Organic Sales Growth
at Investor's Business Daily - Thu Jul 23, 8:37AM CDT
Acquisition-hungry Valeant Pharmaceuticals (VRX) rose more than 5% in the stock market today to a record high, despite weak Q3 earnings guidance, after neatly stepping over analysts' second-quarter revenue and earnings expectations. Valeant was one...
ENDP: 85.90 (-0.62), VRX: 253.84 (+14.92), SHPG: 261.24 (+1.78), RCPT: 228.27 (-0.13), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13), CELG: 139.01 (+0.75)
Eli Lilly (LLY) Stock Climbing on Earnings Beat
at The Street - Thu Jul 23, 8:33AM CDT
Eli Lilly (LLY) shares are gaining after the company beat analysts' top and bottom line expectations and raised its full year guidance.
LLY: 86.76 (+0.38)
Stock Futures Are Mixed as Jobless Claims Drop to 42-Year Low
at The Street - Thu Jul 23, 7:42AM CDT
Stock futures are mixed on Thursday morning as investors digest a range of earnings from the tech sector to industrials.
AXP: 77.01 (-1.98), BAC: 18.18 (-0.27), LLY: 86.76 (+0.38), CI: 154.36 (+3.29), ANTM: 155.21 (+0.11), UA: 95.93 (+6.56), QCOM: 61.78 (-2.41), GM: 31.50 (+1.20), MCD: 97.09 (-0.49), CAT: 76.88 (-2.88), CMCSA: 62.47 (-2.03), DOW: 47.76 (-2.24)
Eli Lilly (LLY) Beats on 2Q Earnings & Revenues - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 7:02AM CDT
Eli Lilly (LLY) Beats on 2Q Earnings & Revenues
LLY: 86.76 (+0.38)
Eli Lilly tops Street 2Q forecasts, raises outlook
AP - Thu Jul 23, 6:38AM CDT
NEW YORK (AP) — Eli Lilly and Co. on Thursday reported better-than-expected second-quarter profit on a boost from its recently acquired animal health unit and raised its outlook.
LLY: 86.76 (+0.38)
Eli Lilly and Company Announces Expansion of San Diego Biotechnology Center
PR Newswire - Thu Jul 23, 5:32AM CDT
Eli Lilly and Company (NYSE: LLY) today revealed plans to expand the Lilly Biotechnology Center located in San Diego, Calif. The expansion will effectively double Lilly's research presence in San Diego as the company seeks to develop new collaborations in one of the world's leading regions for drug research and development.
LLY: 86.76 (+0.38)
Market Wrap: Down Day Across the Board
at The Street - Wed Jul 22, 3:41PM CDT
Tech, telecom stocks lead major averages lower.
MMM: 149.50 (-5.91), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13), CZR: 5.14 (+0.38), GM: 31.50 (+1.20), CRUS: 35.72 (+5.01), MCD: 97.09 (-0.49), CAT: 76.88 (-2.88), FTNT: 46.83 (+4.53), CMCSA: 62.47 (-2.03), DOW: 47.76 (-2.24), SNDK: 63.70 (+9.52), XOMA: 1.04 (+0.04)
3 Big-Cap Drugmakers Who Beat Q2 Earnings Estimates
at Investor's Business Daily - 1 hr 22 mins ago
Large-cap drugmakers Valeant Pharmaceuticals, Eli Lilly and Bristol-Myers Squibb all beat analysts' Q2 estimates, but their stocks went in different directions, as their guidance was more mixed. Valeant (VRX) rose more than 6% after it said total...
VRX: 253.84 (+14.92), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13)
Lilly (Eli) (LLY) Earnings Report: Q2 2015 Conference Call Transcript
at The Street - 1 hr 55 mins ago
The following Lilly (Eli) (LLY) conference call took place on July 23, 2015, 09:00 AM ET. This is a transcript of that earnings call:
LLY: 86.76 (+0.38)
Dow Sheds Yearly Gains as AmEx, Caterpillar Slide
at The Street - Thu Jul 23, 3:07PM CDT
The Dow Jones Industrial Average says goodbye to hard-earned yearly gains on Thursday as major components American Express and Caterpillar sell off.
XLB: 46.09 (-0.68), AXP: 77.01 (-1.98), LLY: 86.76 (+0.38), UA: 95.93 (+6.56), BHP: 36.92 (-0.78), VALE: 5.28 (-0.11), QCOM: 61.78 (-2.41), GM: 31.50 (+1.20), MCD: 97.09 (-0.49), CAT: 76.88 (-2.88), RIO: 38.53 (-0.50), CMCSA: 62.47 (-2.03), SNDK: 63.70 (+9.52)
Eli Lilly, Biogen Present Data at Alzheimer's Association - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 2:55PM CDT
Eli Lilly (LLY) and Biogen presented data on their Alzheimer's disease candidates, solanezumab and aducanumab, respectively at the Alzheimer's Association.
BIIB: 385.05 (-6.69), AGIO: 118.42 (+1.04), AMAG: 71.31 (-1.23), LLY: 86.76 (+0.38)
Dow Turns Negative for 2015 as Losses Accelerate
at The Street - Thu Jul 23, 2:10PM CDT
Stocks are lower on Thursday afternoon as crude oil extends recent lows.
XLB: 46.09 (-0.68), AXP: 77.01 (-1.98), BAC: 18.18 (-0.27), LLY: 86.76 (+0.38), UA: 95.93 (+6.56), IBM: 161.73 (+1.38), VALE: 5.28 (-0.11), BHP: 36.92 (-0.78), QCOM: 61.78 (-2.41), XLK: 42.59 (-0.09), GM: 31.50 (+1.20), MCD: 97.09 (-0.49), CAT: 76.88 (-2.88), RIO: 38.53 (-0.50), MSFT: 46.11 (+0.57), AAPL: 125.16 (-0.06), CMCSA: 62.47 (-2.03), DOW: 47.76 (-2.24), BABA: 83.88 (-0.27)
Don't Sell Qualcomm; Stick With Companies That Have Growth
at The Street - Thu Jul 23, 2:04PM CDT
The CNBC 'Fast Money' traders debate whether now is a good time to sell Qualcomm, and discuss a raft of other stocks.
AMZN: 482.18 (-6.09), NKE: 114.00 (-0.09), FB: 95.44 (-1.60), PFE: 34.78 (-0.10), C: 59.87 (-0.47), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13), INTC: 28.59 (-0.01), HPQ: 31.23 (+0.46), FINL: 27.44 (-0.43), NFLX: 110.10 (-1.40), UA: 95.93 (+6.56), JPM: 69.64 (-0.44), IBM: 161.73 (+1.38), QCOM: 61.78 (-2.41), FFIV: 127.68 (+9.18), CRUS: 35.72 (+5.01), GOOGL: 674.73 (-20.37), FL: 69.90 (-0.36), AAPL: 125.16 (-0.06), FTNT: 46.83 (+4.53), CSCO: 28.01 (+0.48)
Shire Lifts 2015 Guidance On Strong Drug Pipeline
at Investor's Business Daily - Thu Jul 23, 1:42PM CDT
Shire (SHPG) missed analysts' targets for second-quarter earnings and sales but lifted its outlook, citing a strong drug pipeline. The Irish drugmaker's adjusted Q2 earnings per share fell a penny to 88 cents, missing by 5 cents. Operating income on...
VRX: 253.84 (+14.92), SHPG: 261.24 (+1.78), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13)
AmerisourceBergen Beats on 3Q15 Earnings, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 12:36PM CDT
AmerisourceBergen Corp. (ABC) posted earnings of $1.20 per share in the third quarter of fiscal 2015 beating the Zacks Consensus Estimate of $1.15.
ABC: 110.12 (-4.83), WBA: 95.48 (-1.16), LLY: 86.76 (+0.38)
Eli Lilly Beats on 2Q Earnings by Wide Margin, Ups View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Jul 23, 12:10PM CDT
Eli Lilly's (LLY) second quarter results were better-than-expected despite the negative impact of currency movement and genericization.
SNSS: 3.47 (-0.05), LGND: 104.65 (-1.65), AMAG: 71.31 (-1.23), LLY: 86.76 (+0.38)
Lilly Diabetes and NASCAR XFINITY Series Driver Ryan Reed Want You to Think About Your Diabetes Pit Crew
PR Newswire - Thu Jul 23, 11:04AM CDT
To emphasize the importance of a support system in diabetes management, Lilly Diabetes and NASCAR XFINITY Series driver Ryan Reed will kick off the My Diabetes Pit Crew Sweepstakes today in association with the Lilly Diabetes 250, the NASCAR XFINITY Series race in Indianapolis. The sweepstakes hopes to encourage people with diabetes to acknowledge the people who have supported them throughout their diabetes journey.
LLY: 86.76 (+0.38)
Nasdaq Higher as Tech Stocks Rebound
at The Street - Thu Jul 23, 10:00AM CDT
The Nasdaq is the best performer as technology stocks rebound from Wednesday's selloff.
AXP: 77.01 (-1.98), BAC: 18.18 (-0.27), LLY: 86.76 (+0.38), CI: 154.36 (+3.29), UA: 95.93 (+6.56), ANTM: 155.21 (+0.11), IBM: 161.73 (+1.38), QCOM: 61.78 (-2.41), XLK: 42.59 (-0.09), MCD: 97.09 (-0.49), GM: 31.50 (+1.20), CAT: 76.88 (-2.88), MSFT: 46.11 (+0.57), AAPL: 125.16 (-0.06), CMCSA: 62.47 (-2.03), DOW: 47.76 (-2.24), BABA: 83.88 (-0.27)
Lilly, Bristol-Myers Beat Q2 Views, Lift Guidance
at Investor's Business Daily - Thu Jul 23, 9:58AM CDT
Big pharmas Eli Lilly (LLY) and Bristol-Myers Squibb (BMY) both soundly beat Q2 earnings estimates Thursday morning. Both also raised guidance, but not as much as their quarterly beats seemed to warrant. Lilly's profit, excluding one-time items, rose...
LLY: 86.76 (+0.38), BMY: 68.24 (-1.13)
Pharmaceutical Anti-Counterfeiting Technologies Market, 2015-2025 - Authentication Technologies & Track & Trace Technologies
M2 - Thu Jul 23, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3pbvf6/pharmaceutical) has announced the addition of the "Pharmaceutical Anti-Counterfeiting Technologies Market, 2015-2025" report to their offering. The Pharmaceutical Anti-Counterfeiting Technologies, 2015-2025' report provides a comprehensive study of the growing market of anti-counterfeiting technologies being used in the pharmaceutical industry. This study provides extensive details on technologies which offer overt and covert features to enable verification of drugs. In addition, it reviews the different track and trace technologies which enable tracking of a product through the supply chain. Counterfeiting of products is a big concern in several industries such as electronics, cosmetics, tobacco, wine & spirits and fast moving consumer goods. Specifically, within the pharmaceutical market, the magnitude of the problem is relatively high as it has a direct impact on the health of the wider community. It is worth highlighting that the pharmaceutical market is highly attractive for counterfeiters due to several benefits such as high price of patented drugs, lack of proper legislations and high demand of medicines compared to their supply. The primary goal of anti-counterfeiting technologies is to prevent counterfeiting of products; this is done by making it difficult to copy patent protected drugs as well as preventing entry of substandard or fake drugs into the product supply chain. The market can be categorised into two segments, Authentication Technologies (the technologies providing overt and covert security features) and Track & Trace Technologies (the technologies facilitating visibility of products throughout the supply chain). Specifically in the Authentication segment, technologies providing covert security features are very popular and occupy a major share in of the overall authentication market. These technologies are very difficult to mimic and require special instruments / devices for verification of drugs by the manufacturers. Managing supply chain, especially in case of pharmaceutical industry, is a big challenge. Pharmaceuticals supply chains are highly complex and therefore make it an ideal target for counterfeiters. However, recently many developments have taken place to overcome this challenge. Several countries across the globe have passed legislations, making it mandatory to implement serialisation by the manufacturers. Serialisation is being thought as a one stop solution to prevent counterfeiting in the pharmaceutical industry by securing the supply chain. The field has attracted several companies which have developed many technologies with an aim to prevent counterfeiting in the pharma industry. The overall interest continues to rise as is evident from the number of counterfeit incidents and various laws and legislations being passed throughout the world. Small companies that have developed anti-counterfeiting technologies are likely to play a very active role in the near future. Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. Market Overview 5. Authentication: Key Players and Technologies 6. Track And Trace: Key Technologies and the Concept of Serialisation 7. Market Forecast 8. SWOT Analysis 9. Interview Transcripts 10. Conclusion 11. Appendix 1: Tabulated Data 12. Appendix 2: Companies and Organisations Listed Companies Mentioned - 35 of the 125 Companies Featured - 3M - 3S Simons Security Systems - ACG-Worldwide - Acsis - Alcan Packaging - Alien Technology - Alliance for Safe Online Pharmacies - AlpVision - Amcor - Amgen - Applied DNA Sciences - Atlantic Zeiser - Authentix - Avery Dennison - Axway - Ball Packaging - Bilcaretech - Biocode - Bosch Packaging Technology - Canadadrugs.com - Catalent Pharma - Cellular Bioengineering - Central Anti-Counterfeiting Laboratory - Chesapeake (Acquired by The Carlyle Group) - Cognizant - Confidex - Coresonant - Covectra - Deutsche Welle - DiNova Venture Capital - DNA Technologies - Dupont - Eli Lilly and Company - EM Microelectronics - European Alliance of Access to Safe Medicines For more information visit http://www.researchandmarkets.com/research/3p...maceutical
APDN: 2.66 (unch), AMGN: 164.10 (-0.15), LLY: 86.76 (+0.38)
Valeant Earnings Soar On M&A, Organic Sales Growth
at Investor's Business Daily - Thu Jul 23, 8:37AM CDT
Acquisition-hungry Valeant Pharmaceuticals (VRX) rose more than 5% in the stock market today to a record high, despite weak Q3 earnings guidance, after neatly stepping over analysts' second-quarter revenue and earnings expectations. Valeant was one...
ENDP: 85.90 (-0.62), VRX: 253.84 (+14.92), SHPG: 261.24 (+1.78), RCPT: 228.27 (-0.13), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13), CELG: 139.01 (+0.75)
Eli Lilly (LLY) Stock Climbing on Earnings Beat
at The Street - Thu Jul 23, 8:33AM CDT
Eli Lilly (LLY) shares are gaining after the company beat analysts' top and bottom line expectations and raised its full year guidance.
LLY: 86.76 (+0.38)
Stock Futures Are Mixed as Jobless Claims Drop to 42-Year Low
at The Street - Thu Jul 23, 7:42AM CDT
Stock futures are mixed on Thursday morning as investors digest a range of earnings from the tech sector to industrials.
AXP: 77.01 (-1.98), BAC: 18.18 (-0.27), LLY: 86.76 (+0.38), CI: 154.36 (+3.29), ANTM: 155.21 (+0.11), UA: 95.93 (+6.56), QCOM: 61.78 (-2.41), GM: 31.50 (+1.20), MCD: 97.09 (-0.49), CAT: 76.88 (-2.88), CMCSA: 62.47 (-2.03), DOW: 47.76 (-2.24)
Eli Lilly (LLY) Beats on 2Q Earnings & Revenues - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 7:02AM CDT
Eli Lilly (LLY) Beats on 2Q Earnings & Revenues
LLY: 86.76 (+0.38)
Eli Lilly tops Street 2Q forecasts, raises outlook
AP - Thu Jul 23, 6:38AM CDT
NEW YORK (AP) — Eli Lilly and Co. on Thursday reported better-than-expected second-quarter profit on a boost from its recently acquired animal health unit and raised its outlook.
LLY: 86.76 (+0.38)
Eli Lilly and Company Announces Expansion of San Diego Biotechnology Center
PR Newswire - Thu Jul 23, 5:32AM CDT
Eli Lilly and Company (NYSE: LLY) today revealed plans to expand the Lilly Biotechnology Center located in San Diego, Calif. The expansion will effectively double Lilly's research presence in San Diego as the company seeks to develop new collaborations in one of the world's leading regions for drug research and development.
LLY: 86.76 (+0.38)
Market Wrap: Down Day Across the Board
at The Street - Wed Jul 22, 3:41PM CDT
Tech, telecom stocks lead major averages lower.
MMM: 149.50 (-5.91), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13), CZR: 5.14 (+0.38), GM: 31.50 (+1.20), CRUS: 35.72 (+5.01), MCD: 97.09 (-0.49), CAT: 76.88 (-2.88), FTNT: 46.83 (+4.53), CMCSA: 62.47 (-2.03), DOW: 47.76 (-2.24), SNDK: 63.70 (+9.52), XOMA: 1.04 (+0.04)
